scholarly journals Pyrimidine Nucleoside Uptake by Petunia Pollen

1985 ◽  
Vol 79 (3) ◽  
pp. 801-805 ◽  
Author(s):  
Rajender K. Kamboj ◽  
John F. Jackson
Keyword(s):  
Pyrimidine Nucleoside ◽  
Nucleoside Uptake

scholarly journals Regulation of proliferation of LLC-MK2 cells by nucleosides and nucleotides: the role of ecto-enzymes

1996 ◽  
Vol 316 (2) ◽  
pp. 551-557 ◽  
Author(s):  
Raf LEMMENS ◽  
Luc VANDUFFEL ◽  
Henri TEUCHY ◽  
Ognjen CULIC
Keyword(s):  
Cell Proliferation ◽  
Adenine Nucleotides ◽  
Inhibitory Effect ◽  
Pyrimidine Nucleoside ◽  
Purine Nucleotides ◽  
Pyrimidine Nucleotides ◽  
Nucleotides And Nucleosides ◽  
Nucleoside Uptake ◽  
Stimulate Cell Proliferation

1. Using the incorporation of [methyl-3H]thymidine as a proliferation marker, the effects of various nucleosides and nucleotides on endothelial LLC-MK2 cells were studied. We found that ATP, ADP, AMP and adenosine in concentrations of 10 μM or higher stimulate the proliferation of these cells. 2. Inhibition of ecto-ATPase (EC 3.6.1.15), 5´-nucleotidase (EC 3.1.3.5) or alkaline phosphatase (EC 3.1.3.1) significantly diminished the stimulatory effect of ATP, indicating that the effect is primarily caused by adenosine and not by adenine nucleotides. Also, the effect depends only on extracellular nucleosides, since inhibition of nucleoside uptake by dipyridamole has no influence on proliferation. 3. Other purine nucleotides and nucleosides (ITP, GTP, inosine and guanosine) also stimulate cell proliferation, while pyrimidine nucleotides and nucleosides (CTP, UTP, cytidine and uridine) inhibit proliferation. Furthermore, the simultaneous presence of adenosine and any of the other purine nucleosides is not entirely additive in its effect on cell proliferation. At the same time any pyrimidine nucleoside, when added together with adenosine, has the same inhibitory effect as the pyrimidine nucleoside alone. 4. Apparently these proliferative effects are neither caused by any pharmacologically known P1-purinoceptor, nor are they mediated by cyclic AMP, cyclic GMP, or D-myo-inositol 1,4,5-trisphosphate as second messenger, nor by extracellular Ca2+. 5. Therefore, we conclude that various purine and pyrimidine nucleosides can influence the proliferation of LLC-MK2 cells by acting on putative purinergic and pyrimidinergic receptors not previously described.

Insulin Binding and Effects on Pyrimidine Nucleoside Uptake and Incorporation in Cultured Mouse Astrocytes

1987 ◽  
Vol 49 (4) ◽  
pp. 1293-1300 ◽  
Author(s):  
W. Kum ◽  
C. S. Cockram ◽  
S. Q. Zhu ◽  
R. Teoh ◽  
J. Vallance-Owen ◽  
...  
Keyword(s):  
Insulin Binding ◽  
Pyrimidine Nucleoside ◽  
Nucleoside Uptake

scholarly journals Enhancement of pyrimidine nucleoside uptake into K562 and YAC-1 cells by cadeguomycin.

1985 ◽  
Vol 38 (11) ◽  
pp. 1588-1595 ◽  
Author(s):  
RONG TSUN WU ◽  
TAKAYOSHI OKABE ◽  
SUN HEE KIM ◽  
HIDEO SUZUKI ◽  
NOBUO TANAKA
Keyword(s):  
Pyrimidine Nucleoside ◽  
Nucleoside Uptake

Small Molecular Gemcitabine Prodrugs for Cancer Therapy

2020 ◽  
Vol 27 (33) ◽  
pp. 5562-5582 ◽  
Author(s):  
He Miao ◽  
Xuehong Chen ◽  
Yepeng Luan
Keyword(s):  
Drug Resistance ◽  
Side Effects ◽  
Anticancer Drug ◽  
Drug Stability ◽  
Effective Means ◽  
Active Form ◽  
Deoxycytidine Kinase ◽  
High Efficacy ◽  
Pyrimidine Nucleoside ◽  
Design And Synthesis

Gemcitabine as a pyrimidine nucleoside analog anticancer drug has high efficacy for a broad spectrum of solid tumors. Gemcitabine is activated within tumor cells by sequential phosphorylation carried out by deoxycytidine kinase to mono-, di-, and triphosphate nucleotides with the last one as the active form. But the instability, drug resistance and toxicity severely limited its utilization in clinics. In the field of medicinal chemistry, prodrugs have proven to be a very effective means for elevating drug stability and decrease undesirable side effects including the nucleoside anticancer drug such as gemcitabine. Many works have been accomplished in design and synthesis of gemcitabine prodrugs, majority of which were summarized in this review.

Synthesis, Docking and Anti-Tumor Activity of β-L-1,3-Thiazolidine Pyrimidine Nucleoside Analogues

2007 ◽  
Vol 3 (5) ◽  
pp. 425-432 ◽  
Author(s):  
Shimoga Nagaraj Sriharsha ◽  
Karkala Sreedhara Ranganath Pai ◽  
Suhas ◽  
Sheena Shashikanth ◽  
Kandigere Ramaiah Prabhu
Keyword(s):  
Nucleoside Analogues ◽  
Pyrimidine Nucleoside ◽  
Anti Tumor Activity

scholarly journals Development of High‐Performance Pyrimidine Nucleoside and Oligonucleotide Diarylethene Photoswitches

2021 ◽  
Author(s):  
Theresa Kolmar ◽  
Simon M. Büllmann ◽  
Christopher Sarter ◽  
Katharina Höfer ◽  
Andres Jäschke
Keyword(s):  
High Performance ◽  
Pyrimidine Nucleoside

scholarly journals Arabinosyl Cytosine: A Useful Agent in the Treatment of Acute Leukemia in Adults

Blood ◽  
1968 ◽  
Vol 32 (4) ◽  
pp. 507-523 ◽  
Author(s):  
ROSE RUTH ELLISON ◽  
JAMES F. HOLLAND ◽  
MARISE WEIL ◽  
CLAUDE JACQUILLAT ◽  
MICHEL BOIRON ◽  
...  
Keyword(s):  
Remission Rate ◽  
Hemoglobin Level ◽  
Lymphocytic Leukemia ◽  
Acute Myelocytic Leukemia ◽  
Pyrimidine Nucleoside ◽  
Myelocytic Leukemia ◽  
Daily Dose ◽  
Significant Superiority ◽  
Infusion Duration ◽  
Arabinosyl Cytosine

Abstract Arabinosyl cytosine (ara-C), a synthetic pyrimidine nucleoside related to the normal metabolites cytidine and deoxycytidine, has been found capable of producing marrow remission at tolerable doses in acute myelocytic and acute lymphocytic leukemia in adults. There were 16 per cent remissions complete in all aspects, 3 per cent complete except for hemoglobin level, and 6 per cent partial remissions among 180 adults with acute myelocytic leukemia treated with any one of 8 variants of infusion duration or daily dose of ara-C. Twenty-four per cent of 37 adults with acute lymphocytic or unclassified leukemia had complete or partial remissions. The comparison of 1, 4, 12 and 24 hours infusion of ara-C (to total dose tolerated) does not show significant superiority for any one group. The complete remission rate with 1 or 12 hour infusions, however, is 25 per cent (superior to that obtained with 6-mercaptopurine) and the recommended schedule of treatment for ara-C based on these data is, therefore, daily infusions of 100 or 50 mg./m.2 in one hour for approximately 3 to 6 weeks followed by maintenance therapy of once weekly subcutaneous injection of 30 mg./m.2 of ara-C. Platelet transfusions should be available when ara-C is used.

Comprehensive Investigation of the Energetics of Pyrimidine Nucleoside Formation in a Model Prebiotic Reaction

2009 ◽  
Vol 131 (44) ◽  
pp. 16088-16095 ◽  
Author(s):  
Yinghong Sheng ◽  
Heather D. Bean ◽  
Irena Mamajanov ◽  
Nicholas V. Hud ◽  
Jerzy Leszczynski
Keyword(s):  
Pyrimidine Nucleoside ◽  
Comprehensive Investigation
Sign in / Sign up

Export Citation Format

Share Document